#NipponKayaku

Acquired 799,200 shares through share buyback totaling 1,427,473,050 yen in March 2026; acquisition based on Board resolution dated March 28, 2025, has been completed.

Nippon Kayaku acquires shares of a newly established company succeeding part of Fuji Pharma’s pharmaceutical manufacturing business, making it a subsidiary. The business with sales of approximately 3 billion yen is scheduled to be succeeded on October 1, 2026.

From February 1 to February 28, 2026, Nippon Kayaku Co., Ltd. acquired 73,000 shares of treasury stock totaling 129,898,600 yen. The cumulative number of acquired shares reached 10,425,600 shares with a total acquisition amount of 14,777,137,750 yen.

Nippon Kayaku Co., Ltd. announced changes to its executive officers effective April 1, 2026. Mr. Hideyuki Yuya was promoted to Senior Managing Executive Officer, and Ms. Masako Aono and Mr. Shigeru Maeda were appointed as Senior Executive Officers.

Announced the acquisition of 783,300 shares totaling ¥1,378,480,950 through the Tokyo Stock Exchange from January 1 to January 31, 2026.

For the third quarter of the fiscal year ending March 2026, net sales were ¥174.598 billion (4.0% YoY increase), operating income was ¥16.321 billion (9.9% YoY decrease), and net income attributable to owners of parent for the quarter was ¥17.323 billion (30.1% YoY increase).